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At a Glance Commentary
Scientific knowledge on the subject:
Guidelines currently consider the prevention of exacerbations and reducing daily symptoms 
as separate objectives. The “threshold” concept of exacerbations suggests that patients 
report exacerbations when daily symptoms exceed normal day to day variation, and daily 
symptoms pass a threshold of severity above which patients feel the need to take antibiotics. 
Therefore, it is reasonable to hypothesize that patients with a higher daily symptom burden 
may experience more exacerbations. Accordingly, improving daily symptoms should reduce 
exacerbations, particularly in individuals with high symptom burden.
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What this study added to the field:
This is the first study to demonstrate that a high daily respiratory symptom burden, 
measured using the St Georges Respiratory Questionnaire, is associated with increased 
exacerbation risk and shorter time to first exacerbation in bronchiectasis. In a post-hoc 
analysis of a randomized trial, patients with higher daily symptom burdens had increased 
time to first exacerbation, fewer exacerbations, symptom improvements and a trend for 
reduced exacerbation rates when treated with inhaled mannitol compared with control. 
This highlights the importance of therapies focused on symptom improvements in 
preventing exacerbation and the potential need for multimodality treatment in patients 
with the most severe disease.
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Abstract
Rationale: Bronchiectasis guidelines regard treatment to prevent exacerbation and
treatment of daily symptoms as separate objectives.
Objective: We hypothesized that patients with greater symptoms would be at higher
risk of exacerbations and therefore a treatment aimed at reducing daily symptoms would 
also reduce exacerbations in highly symptomatic patients.
Methods: An observational cohort of 333 patients from the East of Scotland (2012-2016). 
Symptoms were either modelled as a continuous variable or patients were classified as high, 
moderate and low symptom burden (>70, 40-70 and <40 using the SGRQ symptom score). 
The hypothesis that exacerbation reductions would only be evident in highly symptomatic 
patients was tested in a post-hoc analysis of a randomized trial of inhaled dry powder 
mannitol (N=461 patients)
Measurement and Main Results: In the observational cohort daily symptoms were a 
significant predictor of future exacerbations (rate ratio [RR] 1.10, 95% confidence interval 
[CI] 1.03-1.17, P=0.005). Patients with higher symptom scores had higher exacerbation rates 
(RR 1.74, 95% CI 1.12-2.72, P=0.01) over 12 months follow-up compared to those with lower 
symptoms. Inhaled mannitol treatment improved the time to first exacerbation (hazard 
ratio [HR] 0.56; 95% CI 0.40-0.77; P<0.001) and the proportion of patients remaining 
exacerbation free for 12 months treatment was higher in the mannitol group (32.7% vs. 
14.6%; RR 2.84, 95% CI 1.40-5.76; P=0.003) but only in highly symptomatic patients. In 
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contrast no benefit was evident in patients with lower symptom burden.
Conclusions: Highly symptomatic patients have increased risk of exacerbations, and 
exacerbation benefit with inhaled mannitol was only evident in patients with high symptom 
burden.
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Introduction
Exacerbations of bronchiectasis are acute events characterized by a worsening of daily 
symptoms usually requiring antibiotic treatment (1, 2). Exacerbations are a major driver of 
disease progression and are associated with poor prognosis and high healthcare costs (3–5). 
Preventing exacerbations are one of key goals in international guidelines for bronchiectasis. 
Macrolides and inhaled antibiotics are recommended as the first-line treatment for patients 
with three or more exacerbations per year (after underlying causes have been treated and 
airway clearance has been optimized) (6, 7). 
The published guidelines consider the prevention of exacerbations and reducing daily 
symptoms as separate objectives (6–8). This is consistent with recent evidence showing that 
prophylactic antibiotic treatments, in particular, reduce exacerbations without a major 
impact on daily symptoms (9, 10). A recent meta-analysis found that inhaled antibiotics 
reduce exacerbation frequency (11), but have no significant impact on daily symptoms. Even 
larger reductions in exacerbation rates were observed for macrolides, again without 
clinically meaningful improvements in symptoms (12). Notably macrolides appear to be 
effective at reducing exacerbations regardless of the severity of baseline symptoms (12).  
The current definition of exacerbation in bronchiectasis is based on an increase in 
respiratory symptoms such as cough, sputum and breathlessness, requiring antibiotic 
treatment (2). It is reasonable to hypothesize that patients with more severe daily 
symptoms would require smaller incremental changes to pass a threshold prompting 
treatment and would therefore be more likely to report exacerbations. (13). Accordingly 
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improving daily symptoms should reduce exacerbations. In chronic obstructive pulmonary 
disease (COPD), several studies have suggested that highly symptomatic patients are more 
likely to have exacerbations. Highly symptomatic COPD patients have clearer reductions in 
exacerbations from bronchodilators than those with low daily symptoms (14, 15). In 
contrast inhaled corticosteroids reduce exacerbations of COPD independent of daily 
symptoms (16). Such a paradigm is not established in bronchiectasis. No previous study has 
investigated the relationship between respiratory symptoms and exacerbations, or 
investigated whether a higher daily symptom burden could identify bronchiectasis patient 
population more likely to have exacerbation benefit with a symptom targeting therapy (6, 
7). 
The dominant symptoms of bronchiectasis are cough and sputum production. For this 
reason, bronchiectasis guidelines recommend airway clearance with or without mucoactive 
drugs as key strategies to reduce symptoms (6-8). The largest study to evaluate a 
mucoactive drug in bronchiectasis found that inhaled dry powder mannitol did not reduce 
exacerbation frequency despite achieving a statistically significant improvement in daily 
symptoms measured using the SGRQ (17).  We have tested the relationship between 
baseline symptoms and exacerbations in an observational cohort study and re-analysed the 
prior randomized controlled trial of inhaled dry powder mannitol (17). We now show that 
highly symptomatic patients are at greater risk of exacerbations and that mannitol achieved 
a reduction in exacerbations in the subgroup of patients with a high symptom burden at 
baseline. 
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This was a prospective observational study (TAYBRIDGE [Tayside Bronchiectasis Registry 
Integrating Datasets, Genomics, and Enrolment into Clinical Trials] registry) at two hospitals 
in the East of Scotland 2012–2016. The study was approved by the East of Scotland 
Research Ethics committee (12/ES/0059), and all patients gave written informed consent. 
Inclusion criteria were age >18 years, high-resolution computed tomography–confirmed 
bronchiectasis, and clinical symptoms consistent with bronchiectasis. Exclusion criteria were 
inability to give informed consent, active nontuberculous mycobacterial infection, active 
allergic bronchopulmonary aspergillosis, active tuberculosis, active malignancy, cystic 
fibrosis, or pulmonary fibrosis with secondary traction bronchiectasis.
Daily symptom burden was measured using SGRQ symptom score. The SGRQ is an 
instrument that is validated in bronchiectasis and has been extensively used in 
bronchiectasis trials (9, 18, 19). We divided patients with 3 groups: high symptom burden 
(>70), moderate symptom burden (40-70), and low symptom burden (<40). These cut-offs 
were determined a priori based on tertiles (tertiles were identified at cut-offs of 47 and 72 
points. Therefore, for clinical ease, 40 and 70 were chosen as cut-offs). A sensitivity analysis 
was performed using the SGRQ total score.  
Severity of disease was evaluated using the bronchiectasis severity index (BSI), as previously 
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described (1). Exacerbations were recorded by patient self-report and further validated by 
reviewing prescription records for antibiotics which are available through electronic medical 
records for all participants. The primary outcome was the relationship between daily 
symptoms and exacerbations over 12 months after baseline. The Secondary outcome was 
time to first exacerbation. 
Mannitol study
We conducted a post hoc analysis of a randomized double-blind controlled trial of inhaled 
dry powder mannitol treatment in bronchiectasis. Results of the original trial have been 
published (17). Patients were randomized (1:1) to 52 weeks treatment with inhaled 
mannitol 400 mg or low-dose mannitol control twice a day. Patients were included if they 
had HRCT confirmed bronchiectasis, baseline FEV1≥40% and ≤85% predicted and ≥1 L, a 
baseline SGRQ score ≥30 and at least 2 exacerbations in the previous year or 4 
exacerbations in the previous 2 years. 
The primary end point was exacerbation rates per patient per year, and the secondary end 
points included time to first exacerbation and quality of life (QoL) measured by change in 
the SGRQ questionnaire. 
Individual participant data from the study was used to firstly confirm the relationship 
between daily symptoms and exacerbation observed in our prospective observational study 
and secondly to examine whether baseline SGRQ symptom score would predict treatment 
response. Treatment response was based on time to first exacerbation, frequency of 
exacerbations, number of subjects experiencing exacerbations and change in SGRQ total 
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score from baseline to week 52. Daily symptom scores were analysed as a continuous 
variable and using the categories according to the cut-off points established in the 
observational cohort study. 
Statistical Analysis
Statistical analysis was performed using the SPSS version 22.0 software (IBM) and R 
software version 3.6.1. Variables were presented by number (percentage), mean (standard 
deviation, SD) or median (interquartile range, IQR), as appropriate. We used the Student’s t 
test, ANOVA tests, or their corresponding non-parametrical tests for continuous variables, 
and chi-square test or Fisher exact test for categorized variables, for the comparisons of 
groups when required. Patients were stratified by SGRQ symptom score at baseline as high 
(>70), moderate (40-70), low (<40) symptom burden. The post hoc analyses of mannitol 
were conducted using the modified intent-to-treat population. Spearman correlation was 
used to examine the relationship between linear variables.
Unadjusted and adjusted analyses were performed using a negative binomial model to 
assess the relationship between baseline SGRQ symptom scores and the frequency of 
exacerbations and hospitalizations. Time to first exacerbation was modelled using Cox's 
proportional hazards models. The rate ratio (RR), hazard ratio (HR) and corresponding 95% 
confidence interval (CI) for exacerbations and time to first exacerbation for the 
uncategorized score represent 10 points increase in SGRQ symptom score when entered as 
a continuous variable. Relevant clinical factors that could affect the outcomes or baseline 
SGRQ symptom scores were included in the adjusted analyses: age, sex, body mass index 
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(BMI), smoking status, FEV1 % of predicted at baseline, radiological score, bacterial isolation 
(Pseudomonas aeruginosa, Haemophilus influenzae and Moraxella catarrhalis), idiopathic 
and post-infective etiologies. To explore the relationship between baseline SGRQ and 
treatment response generalized additive models were fitted to the data from the study 
(using the mgcv library within R 3.6.1) with smooth (spline) terms for both control and 
treatment effects of baseline SGRQ symptom score. The model of exacerbation frequency 
again used a negative binomial error distribution, and a log link function, while that of time 
to first exacerbation used a Cox proportional hazard model. A two-tailed P value of less than 
0.05 was regarded as statistically significant.
Results
Observational Study
Three hundred thirty-three clinically stable patients were recruited for the study. Table 1 
shows the demographic characteristics of the study population. Median age (IQR) was 68 
(60-74) years old, 63.1% were female and median FEV1 was 72 (50-90) % of predicted. Most 
patients were classified as idiopathic (47.7%) and post-infective (18.6%). P. aeruginosa was 
present in the sputum of 13.9% patients at baseline, and median SGRQ symptom score at 
baseline was 59.8 (40.1-79.8) points. Eighty-two patients (24.6%) had low symptom burden, 
127 patients (38.1%) had moderate symptom burden and 124 (37.2%) patients had high 
symptom burden. Patients with high symptom burden had higher BMI, lower FEV1% of 
predicted, lower LCQ total score, a higher number of exacerbations in the previous year, a 
higher isolation of P. aeruginosa, H. influenzae and M. catarrhalis, and a lower proportion of 
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post-infective etiology and stroke. No other differences among groups were found. 
SGRQ symptom score was weakly associated with FEV1 % of predicted (r=-0.37; P<0.001) 
and disease severity (r=0.39; P<0.001 with BSI score and r=0.25; P<0.001 with FACED score) 
(Figure S1 online). Compared to those with moderate and low symptom burden, patients 
with high symptom burden had more exacerbations in the previous year, median (3 [1-5] vs. 
1.5 [0-2] vs. 1 [0-2], P<0.001), lower FEV1 % of predicted (56.1 [42.2-81.9] vs. 74.0 [59.4-91.8] 
vs. 82.9 [68.0-96.9], P<0.001) and more severe disease using the BSI (10 [6-13] vs. 6 [4-8] vs. 
5 [3-7.25], P<0.001) (Figure 1). 
Symptoms at baseline predicted the risk of exacerbations during follow-up. The median 
(interquartile range, IQR) exacerbation rate per patient per year in the following year was 2 
(0-4), 1 (0-2) and 1 (0-1) in the high, moderate and low symptom group (P<0.001), 
respectively.
The results of univariate and multivariate analyses evaluating the relationship between 
the SGRQ symptom score and risk of exacerbations, hospitalizations and time to first 
exacerbation are summarized in Table 2. SGRQ symptom score was a significant predictor of 
future exacerbations (RR 1.10, 95% CI 1.03-1.17, P=0.005 for a 10 point change in SGRQ 
symptom score) and hospitalizations (RR 1.19, 95% CI 1.02-1.35, P=0.03) when entered as a 
continuous variable in the negative binomial model and a trend for shorter time to first 
exacerbation (HR 1.04, 95% CI 0.997-1.10, P=0.27) after adjusting for the relevant 
confounders. Using the cut-offs, high SGRQ symptom score >70 was associated with 
significantly higher exacerbation risk (RR 2.33; 95% CI 1.61-3.37; p<0.001), higher 
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hospitalization risk (RR 6.88, 95% CI 2.59-17.73, P<0.001) and shorter time to first 
exacerbation (HR 1.41; 95% CI 0.99-2.02; p=0.06) compared to patients with lower symptom 
scores. Compared to those with low symptom scores, a moderate SGRQ symptom score 
(40-70) was also associated with higher hospitalization risk (RR 3.53, 95% 1.31-9.54, P=0.01). 
Nevertheless, the difference was not statistically significant (RR 1.07; 0.73 to 1.58; P=0.72 
for exacerbation rate and HR 0.96; 95% CI 0.66-1.38; P=0.30 for time to first exacerbation; 
respectively) in unadjusted analysis when comparing moderate and low symptom groups. 
The higher risk in the highly symptomatic group remained significant even after adjusting 
the effect of potential confounders for the risk of having bronchiectasis exacerbation (RR 
1.74; 95% CI 1.12-2.72; p=0.01) and hospitalization (RR 3.28, 95% CI 1.09-9.88, P=0.04). 
However, high SGRQ score categories were not significantly associated with shorter time to 
first exacerbation compared with the low burden (HR 1.16; 95% CI 0.76-1.77; P=0.49) after 
adjusting the relevant confounders. Notably, the relationship between SGRQ symptom 
score and exacerbation risk were not influenced by disease severity regardless of whether 
this was assessed by BSI or FEV1 % of predicted (Pinteraction=0.25 and Pinteraction=0.62, 
respectively) (Figure S2 online). Repeating these analyses using the SGRQ total score rather 
than the symptom score produced similar results (Table S1 online). Analysis using the 
Leicester cough questionnaire also found similar results (Table S2 online). 
Mannitol Study
The main clinical characteristics of patients included in the study has been reported 
previously (Table S3 online). Median age (IQR) was 63 (53-69) years old, 62.7% were female 
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and median FEV1 was 61.9 (51.9-72.3) % of predicted. Most patients were classified as 
idiopathic (38.8%) and post-infective (33.0%). P. aeruginosa was present in the sputum of 
17.1% patients, and median SGRQ symptom score at baseline was 66.1 (53.9-77.7) points. 
SGRQ symptom score was weakly associated with 24 hour sputum weight (r=0.09; P=0.05) 
and disease severity (r=0.23; P<0.001 with Bronchiectasis Severity Index [BSI] score), but not 
FEV1 % of predicted (r=-0.06, P=0.19), although this analysis is limited by the inclusion 
criteria which required FEV1 between 40 and 85% predicted. Thirty-five patients (7.6%) had 
low symptom burden, 232 patients (50.3%) had moderate symptom burden and 194 (42.1%) 
patients had high symptom burden using the cut-offs established in the observational 
cohort. No statistically significant differences among clinical characteristics according to 
symptom burden were found.
  A total of 380 patients with documented baseline SGRQ symptom score (82.4%) 
completed the double-blind treatment period. 
  The results of univariate and multivariate analyses evaluating the relationship between 
the SGRQ score and risk of exacerbations and time to first exacerbation are summarized in 
Table 3. SGRQ symptom score was a significant predictor of future exacerbations (RR 1.09, 
95% CI 1.02-1.17, P=0.02 for each 10 point increment in the score) and higher symptoms 
were associated with shorter time to first exacerbation (HR 1.09, 95% CI 1.02-1.15, P=0.009) 
after adjusting the relevant confounders. In unadjusted analysis, higher SGRQ symptom 
score categories were associated with significantly higher exacerbation risk (RR 1.71; 95% CI 
1.07-2.76; p=0.03), and shorter time to first exacerbation (HR 1.87; 95% CI 1.16-3.02; p=0.01) 
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compared with low symptom burden. These relationships remained significant even after 
adjusting the effect of potential confounders for the risk of having bronchiectasis 
exacerbation (RR 1.75; 95% CI 1.07-2.86; p=0.03), and shorter time to first exacerbation 
compared with the low burden (HR 1.78; 95% CI 1.09-2.90; p=0.02) after adjusting the 
relevant confounders. We further re-analyzed the data only in the control arm and found 
that higher symptom burden was still associated with higher exacerbation risk (Table S4 
online). We found no modifying effect of disease severity, regardless of whether this was 
assessed by BSI or FEV1 % of predicted on the relationship between symptoms and 
exacerbations (Pinteraction=0.65 and Pinteraction=0.54, respectively). Figure S3 (online) shows 
that patients with higher symptom scores experienced more exacerbations in mild, 
moderate and severe subgroups based on the BSI.  
Primary endpoint. In the original trial, Mannitol treatment was not associated with 
reduced exacerbations compared to the low dose mannitol control with a rate ratio of 0.92 
(95% CI 0.78 to 1.08), P=0.31. We observed a relationship between exacerbation benefit 
with mannitol compared to control with increasing SGRQ (Figure 2). Comparing inhaled 
mannitol with control, there was no benefit in exacerbation rate for patients with low 
symptom burden (RR 1.01; 95% CI 0.41-2.46; P=0.98) and moderate symptom burden (RR 
1.07; 95% CI 0.78-1.47; P=0.69). However, there was a clear trend for exacerbation 
reduction in favor of inhaled mannitol treatment patients with baseline high symptom 
burden (RR 0.76; 95% CI 0.54-1.06; P=0.107) despite lack of statistical significance. We then 
determined the proportion of patients who had no exacerbation for 12 months after 
receiving inhaled mannitol or control. In patients with high symptom burden, we found that 
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32.7% in inhaled mannitol group had no exacerbation compared with 14.6% in control 
group (RR 2.84, 95% CI 1.40-5.76, P=0.003). However, there was no significant difference in 
the proportion of patients who had no exacerbations in patients with low or moderate 
symptom burden (Moderate 26.7% vs. 25.9%, RR 1.05, 95% CI 0.58-1.88, P=0.88; Low 52.6% 
vs. 37.5%; RR 1.85, 95% CI 0.49-7.18; P=0.37).
  Secondary endpoint. For the secondary endpoints of time to first exacerbation, inhaled 
mannitol treatment prolonged the time to first exacerbation (193 days vs. 118 days; HR 0.56; 
95% CI 0.40-0.77; P<0.001) compared with control in the high symptom burden group 
(Figure S4 online). The effect was not different in moderate and low symptom burden 
groups (HR 0.99; 95% CI 0.73-1.34; P=0.94 and HR 0.76; 95% CI 0.31-1.88; P=0.55; 
respectively) (Figure 3). The relationship between SGRQ and time to first exacerbation in the 
generalized additive model is shown in figure 2B. Patients with higher symptom burden had 
a significant improvement in SGRQ total scores above the minimal clinically important 
difference (MCID) in favor of inhaled mannitol treatment compared with control (mean 
difference -5.86; 95% CI -10.49 to -1.22; P=0.014). However, there was no improvement in 
SGRQ total score for patients with moderate (mean difference 1.06; 95% CI -3.22 to 5.33; 
P=0.63) and low symptom burden at baseline (mean difference -0.85; 95% CI -10.41 to 8.71; 
P=0.86) on mannitol compared with control. A decrease in SGRQ total score of greater or 
equal to four points is regard as clinically meaningful. There was no significant difference in 
the percentage of responders in patients with low or moderate symptom burden. In 
patients with high symptom burden, 75% achieved a SGRQ total score decrease above the 
MCID compared with 52.7% of patients in the control group (P=0.001). There were no 
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overall improvements in the FEV1 % of predicted among groups.
Discussion
Exacerbations and daily symptoms have the greatest impact on patient’s survival and 
quality of life in bronchiectasis and therefore reducing exacerbations and relieving daily 
symptoms are the key objectives of therapy. We, for the first time, demonstrate that high 
respiratory symptom burden, regardless of whether these are measured by SGRQ symptom 
score, total score or LCQ total score, is associated with increased exacerbation risk and 
shorter time to first exacerbation in bronchiectasis. This led us to hypothesize that 
improving daily symptom could reduce exacerbations. We then conducted a post-hoc 
analysis of one previously published “negative” randomized controlled trial of inhaled 
mannitol, where we found that only patients with high baseline symptom burden had 
increased time to first exacerbation, fewer exacerbations, symptom improvements and a 
trend for reduced exacerbation rates when treated with inhaled mannitol compared with 
control. These findings suggest that control of daily symptoms can result in reduced 
exacerbations if targeted towards highly symptomatic patients
Guidelines primarily consider these outcomes separately, with a different algorithm for 
patients with 3 or more exacerbations per year where prophylactic antibiotic therapies are 
considered, compared to symptomatic patients with and without exacerbations where 
bronchitic symptoms are treated with airway clearance with or without mucoactive drugs 
and breathlessness treated with pulmonary rehabilitation and bronchodilators where 
appropriate (6, 7). 
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It is intuitive that, as in other chronic conditions like COPD (20–22), there would be a 
relationship between daily symptoms and exacerbations but ours is, to the authors 
knowledge, the first study to specifically address this question. The “threshold” concept of 
exacerbations suggests that patients report exacerbations when daily symptoms exceed 
normal day to day variation, and daily symptoms pass a threshold of severity above which 
patients feel the need to take antibiotics (2, 6, 7). This threshold may be different from 
patient to patient. Some exacerbation events may involve a very large increase in symptoms 
while others may represent only small changes from the patient’s usual baseline. If this 
concept is true, patients with a higher baseline level of symptoms would be closer to the 
threshold and would therefore require a lesser insult to report exacerbations, resulting in a 
higher frequency of events. This model also predicts that reducing daily symptoms would 
therefore result in reduced exacerbation frequency. 
It is puzzling therefore that our recent meta-analysis of macrolides found no impact of 
baseline symptoms on the benefit of macrolides vs placebo for reducing exacerbations (12). 
Patients with an SGRQ score >50 points had a rate ratio of 0.5 (0.28-0.90) for exacerbation 
frequency which was the same as for the patients with SGRQ scores <30 (0.50 95% CI 
0.29-0.84). The 50% reduction in exacerbations was accompanied by only a borderline 
improvement in symptoms. Likewise, in the ORBIT studies of inhaled liposomal ciprofloxacin 
there was a reduction in the frequency of exacerbations in the pooled analysis of both 
replicate trials (10), but no benefit in terms of symptoms and similar results were observed 
in the large RESPIRE programme (9, 23). It seems therefore that for antibiotics, the benefit 
in exacerbation reduction is disconnected from baseline symptoms or symptom responses. 
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Nevertheless, the finding in recent studies that pulmonary rehabilitation and airway 
clearance can reduce exacerbation frequency suggests that at least a subset of 
exacerbations are symptom driven and therefore preventable with treatment focused on 
symptoms (24–26). It is tempting therefore to speculate that antibiotics prevent a subset of 
exacerbations that are inflammation and infection driven (27, 28), while symptomatic 
therapies may prevent a different exacerbation subtype. This is analogous to the established 
concept in COPD that bronchodilators reduce exacerbations through reducing symptoms 
and are therefore indicated as first line treatment for patients with symptoms and 
exacerbations (GOLD D) while inhaled corticosteroids appear to reduce exacerbations 
independent of symptom reductions and are therefore indicated both in patients with 
exacerbations and low symptom burden (GOLD C) and GOLD D patients that continue to 
exacerbation despite symptomatic therapy (16). Confirming that this concept also applies in 
bronchiectasis will require further experimental work including testing the role of airway 
inflammation as a mediator in these relationships. This concept would predict that 
anti-inflammatory therapies such as neutrophil elastase inhibitors may reduce 
exacerbations without having a large effect on symptoms.  
Our results nevertheless support the “treatable traits” concept in management of 
bronchiectasis. In patients with frequent exacerbations with a low symptom burden, it may 
be adequate to treat such patients with airway clearance and the addition of anti-infective 
or anti-inflammatory therapy with macrolides, inhaled antibiotics or inhaled corticosteroids 
if they continue to frequently exacerbate. In contrast, in patients with a high symptom 
burden, symptomatic treatment with airway clearance and mucoactive drugs may be 
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effective to prevent exacerbations, contributing to antibiotic stewardship. In patient with 
both a high symptom burden and a high frequency of exacerbations, there is likely to be 
requirement for therapy directed at both aspects of disease, using phenotyping/endotyping 
to identify the most appropriate therapies (29, 30). 
Our analysis has limitations. The observational cohort and mannitol trials were conducted 
prior to the validation of the quality of life bronchiectasis questionnaire and bronchiectasis 
heath questionnaire which are specific for bronchiectasis (31–33), but we and others have 
demonstrated that the QOL-B and SGRQ are highly correlated and the SGRQ is the most 
widely used quality of life tool in bronchiectasis research and particularly in clinical trials (31, 
33, 34). The analysis of the mannitol study is post-hoc and results should be considered as 
hypothesis generating. 
In summary, we have demonstrated that patients with a high burden of symptoms are at 
higher risk of exacerbations even after adjustment for underlying severity of disease. This 
highlights the importance of therapies focused on symptom improvements and the 
potential need for multimodality treatment in patients with the most severe disease.
Page 20 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
References
1. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, 
Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT. The bronchiectasis 
severity index an international derivation and validation study. Am J Respir Crit Care 
Med 2014;189:576–585.
2. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, 
Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, 
Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, 
Vendrell M, Welte T, Wilson R, Wong C, O’Donnell A, Aksamit T. Pulmonary 
exacerbation in adults with bronchiectasis: a consensus definition for clinical research. 
Eur Respir J 2017;49: 1700051.
3. Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, 
Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, 
Polverino E, De Soyza A, McDonnell MJ. Characterization of the “frequent exacerbator 
phenotype” in bronchiectasis. Am J Respir Crit Care Med 2018;197:1410–1420.
4. Diel R, Chalmers JD, Rabe KF, Nienhaus A, Loddenkemper R, Ringshausen FC. 
Economic burden of bronchiectasis in Germany. Eur Respir J 2019;53:1802033.
5. Goeminne PC, Hernandez F, Diel R, Filonenko A, Hughes R, Juelich F, Solomon GM, 
Upton A, Wichmann K, Xu W, Chalmers JD. The economic burden of bronchiectasis – 
known and unknown: a systematic review. BMC Pulm Med 2019;19:54.
Page 21 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
6. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, 
Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, 
Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, 
Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. European 
Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir 
J 2017;50:1700629.
7. T Hill A, L Sullivan A, D Chalmers J, De Soyza A, Stuart Elborn J, Andres Floto R, Grillo L, 
Gruffydd-Jones K, Harvey A, S Haworth C, Hiscocks E, R Hurst J, Johnson C, Peter 
Kelleher W, Bedi P, Payne K, Saleh H, J Screaton N, Smith M, Tunney M, Whitters D, 
Wilson R, R Loebinger M. British Thoracic Society Guideline for bronchiectasis in 
adults. Thorax 2019;74:1–69.
8. Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, 
Vendrell M, Polverino E, de Gracia J, Prados C. Spanish Guidelines on Treatment of 
Bronchiectasis in Adults. Arch Bronconeumol 2018;54:88–98.
9. De Soyza A, Aksamit T, Bandel T-J, Criollo M, Elborn JS, Operschall E, Polverino E, Roth 
K, Winthrop KL, Wilson R. RESPIRE 1: a phase III placebo-controlled randomised trial 
of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur 
Respir J 2018;51:1702052.
10. Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, 
Wanner A, O’Donnell AE. Inhaled liposomal ciprofloxacin in patients with non-cystic 
fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa 
Page 22 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
(ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med 
2019;7:213–226.
11. Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled 
antibiotics for the treatment of bronchiectasis in adults: a systematic review and 
meta-analysis. Lancet Respir Med 2019;7;855-869.
12. Chalmers JD, Boersma W, Lonergan M, Jayaram L, Crichton ML, Karalus N, Taylor SL, 
Martin ML, Burr LD, Wong C, Altenburg J. Long-term macrolide antibiotics for the 
treatment of bronchiectasis in adults: an individual participant data meta-analysis. 
Lancet Respir Med 2019;7;845-854.
13. Mackay AJ, Kostikas K, Murray L, Martinez FJ, Miravitlles M, Donaldson G, Banerji D, 
Patalano F, Wedzicha JA. Patient-reported Outcomes for the Detection, 
Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease 
Exacerbations. Am J Respir Crit Care Med 2018;198:730–738.
14. Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D. Effects 
of baseline symptom burden on treatment response in COPD. Int J Chron Obstruct 
Pulmon Dis 2019;14:181–194.
15. Martinez FJ, Fabbri LM, Ferguson GT, Orevillo C, Darken P, Martin UJ, Reisner C. 
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered 
Dose Inhaler in COPD. Chest 2017;152:1169–1178.
16. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin 
Page 23 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, 
Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C. Global Strategy for 
the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the 
GOLD science committee report 2019. Eur Respir J 2019;53:1900164.
17. Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJA, O’Dochartaigh C, 
Van Haren EHJ, Vidal LO, Welte T, Fox HG, Wu J, Charlton B. Inhaled mannitol for 
non-cystic fibrosis bronchiectasis: A randomised, controlled trial. Thorax 
2014;69:1073–1079.
18. WILSON CB, JONES PW, O’LEARY CJ, COLE PJ, WILSON R. Validation of the St. George’s 
Respiratory Questionnaire in Bronchiectasis. Am J Respir Crit Care Med 
1997;156:536–541.
19. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, 
Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations 
in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, 
placebo-controlled trial. Lancet 2012;380:660–667.
20. Lee S Do, Huang MS, Kang J, Lin CH, Park MJ, Oh YM, Kwon N, Jones PW, Sajkov D. 
The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk 
patients. Respir Med 2014;108:600–608.
21. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, 
Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Lazarus SC, Martinez FJ, Paine R, 
Page 24 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
Rennard S, Tashkin DP, Han MK. Clinical significance of symptoms in smokers with 
preserved pulmonary function. N Engl J Med 2016;374:1811–1821.
22. Martinez CH, Murray S, Barr RG, Bleecker E, Bowler RP, Christenson SA, Comellas AP, 
Cooper CB, Couper D, Criner GJ, Curtis JL, Dransfield MT, Hansel NN, Hoffman EA, 
Kanner RE, Kleerup E, Krishnan JA, Lazarus SC, Leidy NK, O’Neal W, Martinez FJ, Paine 
R, Rennard SI, Tashkin DP, Woodruff PG, Han MK. Respiratory symptoms items from 
the COPD assessment test identify ever-smokers with preserved lung function at 
higher risk for poor respiratory outcomes an analysis of the subpopulations and 
intermediate outcome measures in COPD Study cohort. Ann Am Thorac Soc 
2017;14:636–642.
23. Aksamit T, De Soyza A, Bandel T-J, Criollo M, Elborn JS, Operschall E, Polverino E, Roth 
K, Winthrop KL, Wilson R. RESPIRE 2: a phase III placebo-controlled randomised trial 
of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur 
Respir J 2018;51:1702053.
24. Muñoz G, de Gracia J, Buxó M, Alvarez A, Vendrell M. Long-term benefits of airway 
clearance in bronchiectasis: a randomised placebo-controlled trial. Eur Respir J 
2018;51:1701926.
25. Lee AL, Hill CJ, Cecins N, Jenkins S, McDonald CF, Burge AT, Rautela L, Stirling RG, 
Thompson PJ, Holland AE. The short and long term effects of exercise training in 
non-cystic fibrosis bronchiectasis – a randomised controlled trial. Respir Res 
2014;15:44.
Page 25 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
26. Lee AL, Hill CJ, McDonald CF, Holland AE. Pulmonary Rehabilitation in Individuals With 
Non–Cystic Fibrosis Bronchiectasis: A Systematic Review. Arch Phys Med Rehabil 
2017;98:774-782.
27. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, Dicker A, Wrobel 
K, Elborn JS, Walker B, Martin SL, Marshall SE, Huang JT-J, Fardon TC. Neutrophil 
Elastase Activity Is Associated with Exacerbations and Lung Function Decline in 
Bronchiectasis. Am J Respir Crit Care Med 2016;195:1384–1393.
28. Gao Y, Guan W, Xu G, Lin Z, Tang Y, Lin Z, Gao Y, Li H, Zhong N, Zhang G, Chen R. The 
Role of Viral Infection in Pulmonary Exacerbations of Bronchiectasis in Adults: A 
Prospective Study. Chest 2015;147:1635–1643.
29. Boaventura R, Sibila O, Agusti A, Chalmers JD. Treatable traits in bronchiectasis. Eur 
Respir J 2018;52:1801269.
30. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, Humbert M, Jones P, 
Gibson PG, Vestbo J, Beasley R, Pavord ID. Treatable traits: toward precision medicine 
of chronic airway diseases. Eur Respir J 2016;47:410–419.
31. Spinou A, Siegert RJ, Guan W, Patel AS, Gosker HR, Lee KK, Elston C, Loebinger MR, 
Wilson R, Garrod R, Birring SS. The development and validation of the Bronchiectasis 
Health Questionnaire. Eur Respir J 2017;49:1601532.
32. Quittner AL, O’Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O’Riordan TG, 
Barker AF. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses 
Page 26 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
and determination of minimal important difference scores. Thorax 2015;70:12–20.
33. Quittner AL, Marciel KK, Salathe MA, O’Donnell AE, Gotfried MH, Ilowite JS, Metersky 
ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O’Riordan TG, Barker AF. A 
Preliminary Quality of Life Questionnaire-Bronchiectasis: A Patient-Reported 
Outcome Measure for Bronchiectasis. Chest 2014;146:437–448.
34. Crichton ML, Aliberti S, Chalmers JD. A systematic review of pharmacotherapeutic 
clinical trial end-points for bronchiectasis in adults. Eur Respir Rev 2019;28:180108.
Page 27 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
Figure legends
Figure 1. Association of low (SGRQ symptom score<40 points), moderate (SGRQ symptom 
score 40-70 points) and high (SGRQ symptom score>70 points) symptom burden with the 
number of exacerbations in previous year (Panel A), Bronchiectasis Severity Index (BSI) 
(Panel B) and Forced expiratory volume in 1 second (Panel C). p value is from comparison of 
all groups (Kruskall-Wallis test for A-C)
Figure 2. Relationship between baseline SGRQ symptom score and exacerbation outcomes 
in the mannitol trial. The figure shows the estimated ratio between the treatment and 
control arms for different SGRQ scores, with 95% confidence intervals. 
Figure 3. Hazard ratio for time to first exacerbation in patients with bronchiectasis divided 
into high, moderate and low symptom burden. The vertical dotted line represents a hazard 
ratio of 1.
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Burden (n=124) P value
Age, yr, median (IQR) 68 (60-74) 67 (60.75-74.25) 68 (60-74) 68 (58-74) 0.76
Female sex 210 (63.1%) 54 (65.9%) 80 (63%) 76 (61.3%) 0.806
FEV1% predicted, 
median (IQR) 72 (50-90) 82.9 (68.0-96.9) 74.0 (59.4-91.8) 56.1 (42.2-81.9) <0.001
BMI, kg/m2, median 
(IQR) 25.3 (21.8-28.6) 24.7 (21.3-27.3) 24.9 (22.0-28.4) 26.7 (22.6-30.7) 0.01
Smoking status      
  Never 203 (61%) 53 (64.6%) 79 (62.2%) 71 (57.3%) 0.11
  Ex-smoker 116 (34.8%) 27 (32.9%) 46 (36.2%) 43 (34.7%)
  Current 14 (4.2%) 2 (2.4%) 2 (1.6%) 10 (8.1%)
Exacerbation in the 
preceding year 1 (0-3) 1 (0-2) 1.5 (0-2) 3 (1-5) <0.001
Radiologic score, median 
(IQR) 3 (2-6) 3 (2-5) 3.5 (2-6） 3 (2-7) 0.24
Pseudomonas 
aeruginosa 47 (13.9%) 2 (2.4%) 16 (12.6%) 29 (23.4%) <0.001
Haemophilus influenzae 109 (32.2%) 25 (30.5%) 28 (22.0%) 54 (43.5%) 0.001
Moraxella catarrhalis 42 (12.4%) 7 (8.5%) 11 (8.7%) 23 (18.5%) 0.03
Staphylococcus aureus 30 (8.8%) 4 (4.9%) 14 (11.0%) 11 (8.9%) 0.28
Enterobacteriaceae 42 (12.4%) 6 (7.3%) 19 (15.0%) 17 (13.7%) 0.24
SGRQ symptom score, 
median (IQR) 59.8 (40.1-79.8) 27.5 (15.2-32.7) 55.5 (48.6-61.6) 85.8 (77.8-90.6) <0.001
LCQ total score   
median (IQR) 14.3 (10.6-17.9) 18.9 (16.8-20.1) 14.9 (11.9-17.6) 10.2 (7.9-13.1) <0.001
Etiology
 Idiopathic 159 (47.7%) 48 (58.5%) 51 (40.2%) 60 (48.4%) 0.03
 Post-infection 62 (18.6%) 16 (19.5%) 32 (25.2%) 14 (11.3%) 0.02
 Previous ABPA 29 (8.7%) 4 (4.9%) 12 (9.4%) 13 (10.5%) 0.31
 Asthma 9 (2.7%) 2 (2.4%) 3 (2.4%) 4 (3.2%) 0.90
 COPD 14 (4.2%) 4 (4.9%) 5 (3.9%) 5 (4%) 0.94
 Rheumatoid arthritis 13 (3.9%) 2 (2.4%) 3 (2.4%) 8 (6.5%) 0.19
 Immunodeficiency 16 (4.8%) 3 (3.7%) 6 (4.7%) 7 (5.6%) 0.80
 Sarcoidosis 6 (1.8%) 1 (1.2%) 3 (2.4%) 2 (1.6%) 0.82
 IBD 9 (2.7%) 0 (0) 5 (3.9%) 4 (3.2%) 0.07
Comorbidities
 Cardiac disease 66 (19.8%) 16 (19.5%) 29 (22.8%) 21 (16.9%) 0.50
 Stoke 31 (9.3%) 11 (13.4%) 15 (11.8%) 5 (4.0%) 0.04
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 Diabetes 39 (11.7%) 15 (18.3%) 6 (4.7%) 18 (14.5%) 0.006
 Osteoporosis 20 (6.0%) 5 (6.1%) 6 (4.7%) 9 (7.3%) 0.70
Data were presented as mean (standard deviation, SD), median (interquartile range, IQR), number (%) as appropriate. 
Abbreviation: ABPA=allergic bronchopulmonary aspergillosis; BMI=body mass index kg/m2; COPD=chronic obstructive 
pulmonary disease; FEV1=forced expiratory volume in 1 s; IBD=Inflammatory bowel disease; LCQ=Leicester Cough 
Questionnaire; SGRQ=St. George's Respiratory Questionnaire; yr=year; 
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Table 2. Relationship Between Baseline SGRQ Symptom Score and Exacerbations in Observational Study
Exacerbations (any) 　 Hospitalizations 　 Time to first exacerbations








Hazard ratio       
(95% CI)
P value
Uncategorized score         
(unadjusted)
1.15 (1.09-1.21) <0.001 1.27 (1.15-1.39) <0.001 1.07 (1.01-1.13) 0.02
Uncategorized score 
(adjusted)
1.10 (1.03-1.17) 0.005 1.19 (1.02-1.35) 0.03 1.04 (0.997-1.10) 0.27
Categorized score     
(unadjusted)
  Low (<40) 1 1 1
  Moderate (40-70) 1.07 (0.73-1.58) 0.72 3.53 (1.31-9.54) 0.01 0.96 (0.66-1.38) 0.3
  High (>70) 2.33 (1.61-3.37) <0.001 6.88 (2.59-17.73) <0.001 1.41 (0.99-2.02) 0.06
Categorized score     
(adjusted)
  Low (<40) 1
  Moderate (40-70) 1.01 (0.66-1.54) 0.96 2.29 (0.77-6.83) 0.14 0.96 (0.65-1.43) 0.84
  High (>70) 1.74 (1.12-2.72) 0.01 　 3.28 (1.09-9.88) 0.04 　 1.16 (0.76-1.77) 0.49
*Adjusted for age, sex, BMI, smoking, FEV1 % of predicted, Pseudomonas aeruginosa isolation, Haemophilus influenzae isolation, 
Moraxella catarrhalis isolation, idiopathic bronchiectasis, post-infective bronchiectasis, radiological score. CI=confidence interval.
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Table 3. Relationship Between Baseline SGRQ Symptom Score and Exacerbations in Mannitol Study
Exacerbations Time to first exacerbations
SGRQ symptom score Rate ratio                 
(95% CI)
P value
Hazard ratio       
(95% CI)
P value
Uncategorized score         
(unadjusted) 1.09 (1.02-1.16) 0.011 1.10 (1.04-1.17) 0.001
Uncategorized score 
(adjusted)* 1.09 (1.02-1.17) 0.017 1.09 (1.02-1.15) 0.009
Categorized score     
(unadjusted)
  Low (<40) 1 1
  Moderate (40-70) 1.45 (0.91-2.33) 0.12 1.74 (1.08-2.79) 0.02
  High (>70) 1.71 (1.07-2.76) 0.03
1.87 (1.16-3.02）
0.01
Categorized score     
(adjusted)*
  Low (<40) 1 1
  Moderate (40-70) 1.50 (0.92-2.45) 0.10 1.73 (1.07-2.80) 0.03
  High (>70) 1.75 (1.07-2.86) 0.03 1.78 (1.09-2.90) 0.02
*Adjusted for age, sex, BMI, smoking, FEV1 % of predicted, Pseudomonas aeruginosa isolation, 
Haemophilus influenzae isolation, Moraxella catarrhalis isolation, idiopathic bronchiectasis, post-infective 
bronchiectasis, radiological score. CI=confidence interval.
Page 32 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
 
Figure 1. Association of low (SGRQ symptom score<40 points), moderate (SGRQ symptom score 40-70 
points) and high (SGRQ symptom score>70 points) symptom burden with the number of exacerbations in 
previous year (Panel A), Bronchiectasis Severity Index (BSI) (Panel B) and Forced expiratory volume in 1 
second (Panel C). p value is from comparison of all groups (Kruskall-Wallis test for A-C) 
312x93mm (300 x 300 DPI) 
Page 33 of 50
 AJRCCM Articles in Press. Published February 25, 2020 as 10.1164/rccm.201910-1972OC 
 Copyright © 2020 by the American Thoracic Society 
 
Figure 2. Relationship between baseline SGRQ symptom score and exacerbation outcomes in the mannitol 
trial. The figure shows the estimated ratio between the treatment and control arms for different SGRQ 
scores, with 95% confidence intervals. 
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Figure 3. Hazard ratio for time to first exacerbation in patients with bronchiectasis divided into high, 
moderate and low symptom burden. The vertical dotted line represents a hazard ratio of 1. 
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Supplementary methods
Leicester cough questionnaire (LCQ): daily symptom burden was also measured using LCQ total 
score, an instrument that is validated in bronchiectasis for assessing cough (1). We divided 
patients with 3 groups: high symptom burden (<11), moderate symptom burden (11-17), and 
low symptom burden (>17). These cut-offs were determined based on tertiles (tertiles were 
identified based on cut-offs of 11.68 and 16.86 points. Therefore, for clinical ease, 11 and 17 
were chosen as cut-offs).
Supplementary results
Observational study
The results of univariate and multivariate analyses evaluating the relationship between the 
SGRQ total score and risk of exacerbations and time to first exacerbation are summarized in 
Table S1. SGRQ total score was still a significant predictor of future exacerbations (RR 1.15, 95% 
CI 1.07-1.23, P<0.0001) and higher SGRQ total score was associated with shorter time to first 
exacerbation (HR 1.11, 95% CI 1.01-1.19, P=0.004) after adjusting the relevant confounders.
The results of univariate and multivariate analyses evaluating the relationship between the LCQ 
total score and risk of exacerbations and time to first exacerbation are summarized in Table S2. 
LCQ total score was a significant predictor of future exacerbations when entered as a 
continuous variable in the negative binomial model (RR 0.95, 95% CI 0.91-0.98, P=0.005) and a 
trend for shorter time to first exacerbation (HR 0.97, 95% CI 0.94-1.01, P=0.14) after adjusting 
the relevant confounders. Using the cutoffs, high LCQ total score <11 was associated with 
significantly higher exacerbation risk (RR 2.18; 95% CI 1.51-3.15; p<0.001), and a shorter time to 
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first exacerbation (HR 1.45; 95% CI 1.02-2.06; p=0.04) compared to patients with lower LCQ 
total score. Compared to those with low symptom scores, a moderate LCQ total score was also 
associated with higher exacerbation risk (RR 1.49; 95% CI 1.06-2.10; P=0.02). The difference for 
time to first exacerbation was not statistically significant (HR 0.99; 95% CI 0.71-1.37; P=0.93) in 
unadjusted analysis when comparing moderate and low LCQ total score categories. The higher 
risk in the highly symptomatic group remained significant even after adjusting the effect of 
potential confounders for the risk of having bronchiectasis exacerbation (RR 1.70; 95% CI 1.09-
2.64; p=0.02), but these associations were lost for time to first exacerbation (HR 1.33; 95% CI 
0.89-1.99; P=0.17).
In addition, the relationship between symptoms and exacerbation risk classified by 
bronchiectasis severity index (BSI) and FEV1 % of predicted as measures of disease severity, 
respectively, were shown in Figure S2. The RR and 95% CI for exacerbation rate was 1.10 (1.00-
1.20, P=0.05) in patients with severe bronchiectasis (BSI≥9 points), as compared with 1.07 
(0.998-1.16, P=0.15) in patients with moderate bronchiectasis (BSI=5-8 points), and 1.07 (0.994-
1.02, P=0.30) in patients with mild bronchiectasis (BSI=0-4 points). And the RR and 95% CI for 
exacerbation rate was 1.19 (1.05-1.34, P=0.009) in patients with FEV1 % of predicted<50%, as 
compared with 1.15 (1.05-1.26, P=0.003) in patients with FEV1 % of predicted≥50%, ≤80%, and 
1.13 (1.04-1.22, P=0.005) in patients with FEV1 % of predicted >80%. 
Mannitol study
The relationship between symptoms and exacerbation risk classified by bronchiectasis severity 
index (BSI) and FEV1 % of predicted as measures of disease severity, respectively, were shown 
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in Figure S3. The RR and 95% CI for exacerbation rate was 1.09 (0.994-1.24, P=0.26) in patients 
with severe bronchiectasis (BSI≥9 points), as compared with 1.06 (0.996-1.15, P=0.26) in 
patients with moderate bronchiectasis (BSI=5-8 points), and 1.12 (0.996-1.29, P=0.13) in 
patients with mild bronchiectasis (BSI=0-4 points). And the RR and 95% CI for exacerbation rate 
was 1.15 (0.997-1.33, P=0.10) in patients with FEV1 % of predicted<50%, as compared with 1.07 
(0.999-1.16, P=0.09) in patients with FEV1 % of predicted≥50%, ≤80%, and 1.13 (0.991-1.37, 
P=0.25) in patients with FEV1 % of predicted >80%. 
The results of univariate and multivariate analyses evaluating the relationship between the 
SGRQ symptom score in control arm and risk of exacerbations and time to first exacerbation in 
control arm are summarized in Table S4. SGRQ symptom score was a significant predictor of 
future exacerbations (RR 1.14, 95% CI 1.03-1.25, P=0.01) and higher symptoms were associated 
with shorter time to first exacerbation (HR 1.14, 95% CI 1.05-1.24, P=0.002) after adjusting the 
relevant confounders. In unadjusted analysis, higher SGRQ symptom score categories were 
associated with a trend of higher exacerbation risk (RR 1.97; 95% CI 0.98-3.96; p=0.06), and 
shorter time to first exacerbation (HR 2.21; 95% CI 1.14-4.28; p=0.02) compared with low 
symptom burden. These relationships remained significant even after adjusting the effect of 
potential confounders for the risk of shorter time to first exacerbation compared with the low 
burden (HR 2.09; 95% CI 1.06-4.12; p=0.033). 
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Figure Legends
Figure S1. Correlation between SGRQ symptom score and the number of exacerbations in 
previous year (rho=0.39, P<0.0001) (Panel A), bronchiectasis severity index (rho=0.39, 
P<0.0001) (Panel B) and FEV1 % of predicted in Observational study (rho=-0.37, P<0.0001) Panel 
C). 
Figure S2. Rate ratio for baseline SGRQ symptom score and future exacerbation risk in patients 
with different disease severity assessed by bronchiectasis severity index (Panel A) and FEV1 % 
of predicted (Panel B) in Observational study. Error bars represent 95% CI. The vertical dotted 
line represents a rate ratio of 1. 
Figure S3. Rate ratio for baseline SGRQ symptom score and future exacerbation risk in patients 
with different disease severity assessed by bronchiectasis severity index (Panel A) and FEV1 % 
of predicted (Panel B) in Mannitol study. Error bars represent 95% CI. The vertical dotted line 
represents a rate ratio of 1. 
Figure S4. Kaplan-Meier plot of the time to first exacerbation in high symptomatic patients.
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Table S1. Relationship Between Baseline SGRQ Total Score and Exacerbations in Observational Study
Exacerbations 　 Time to first exacerbations
SGRQ total score
Rate ratio       (95% CI)
p value 　
Hazard ratio       (95% 
CI)
p value
Uncategorized score         
(unadjusted) 1.16 (1.11-1.22) <0.0001 1.13 (1.06-1.19) <0.0001
Uncategorized score 
(adjusted)* 1.15 (1.07-1.22) <0.0001 　 1.11 (1.04-1.19) 0.004
*Adjust for age, gender, BMI, FEV1 % of predicted, smoking status, Pseudomonas aeruginosa isolation, 
Haemophilus influenzae isolation, Moraxella catarrhalis isolation, radiological score, idiopathic 
bronchiectasis, post-infective bronchiectasis
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Table S2. Relationship Between Baseline LCQ Total Score and Exacerbations in Observational Study
Exacerbations 　 Time to first exacerbations
LCQ total score
Rate ratio        (95% CI) p value 　 Hazard ratio       (95% CI) p value
Uncategorized score         
(unadjusted) 0.93 (0.90-0.95) <0.001 0.97 (0.94-1.00) 0.02
Uncategorized score 
(adjusted)* 0.95 (0.91-0.98) 0.005 0.97 (0.94-1.01) 0.14
Categorized score     
(unadjusted)
  Low (>17) 1
  Moderate (11-17) 1.49 (1.06-2.10) 0.02 0.99 (0.71-1.37) 0.93
  High (<11) 2.18 (1.51-3.15) <0.001 1.45 (1.02-2.06) 0.04
Categorized score     
(adjusted)*
  Low (>17) 1
  Moderate (11-17) 1.48 (1.02-2.16) 0.04 1.03 (0.72-1.47) 0.88
  High (<11) 1.70 (1.09-2.64) 0.02 　 1.33 (0.89-1.99) 0.17
*Adjust for age, gender, BMI, FEV1 % of predicted, smoking status, Pseudomonas aeruginosa isolation, 
Haemophilus influenzae isolation, Moraxella catarrhalis isolation, radiological score, idiopathic bronchiectasis, 
post-infective bronchiectasis
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Burden (n=194) P value
Age, yr, median 
(IQR) 63 (53-69) 68 (57-70) 62 (50.3-69) 63 (55.8-69) 0.24
Female sex 289 (62.7%） 23 (65.7%) 149 (64.2%) 117 (60.3%) 0.66
FEV1% predicted, 
median (IQR) 61.9 (51.9-72.3) 67.3 (59.0-76.0) 61.1 (50.3-71.5) 61.6 (51.8-72.5) 0.12
BMI, kg/m2,        
median (IQR) 25.6 (22.4-29.1) 26.2 (21.6-28.7) 25.1 (21.8-28.3) 26.4 (22.8-29.7) 0.04
Ex-smoker 181 (39.3%) 12 (34.3%) 82 (35.3%) 87 (44.8%) 0.11
Exacerbation in the 
preceding year 3 (2-4) 2 (2-4) 3 (2-4) 3 (2-4) 0.14
Pseudomonas 
aeruginosa 79 (17.1%) 2 (5.7%) 41 (17.7%) 36 (18.6%) 0.11
Haemophilus 
influenzae 67 (14.5%) 7 (20%) 30 (12.9%) 30 (15.5%) 0.48
Moraxella 
catarrhalis 16 (3.5%) 3 (8.6%) 6 (2.6%) 7 (3.6%) 0.28
Staphylococcus 
aureus 13 (2.8%) 2 (5.7%) 6 (2.6%) 5 (2.6%) 0.63
Streptococcus 
pneumoniae 20 (4.3%) 2 (5.7%) 10 (4.3%) 8 (4.1%) 0.92
SGRQ symptom 
score, median (IQR) 66.1 (53.9-77.7) 32.4 (27.2-37.8) 57.7 (50.7-64.5) 79.4 (75.2-85.0) <0.001
Etiology
  Idiopathic 179 (38.8%) 14 (40.0%) 99 (42.7%) 66 (34.0%) 0.19
  Post-infection 152 (33.0%) 15 (42.9%) 81 (34.9%) 56 (28.9%) 0.18
Data were presented as mean (standard deviation, SD), median (interquartile range, IQR), number (%) as 
appropriate. Abbreviation: BMI=body mass index kg/m2; FEV1=forced expiratory volume in 1 s; SGRQ=St. George's 
Respiratory Questionnaire; yr=year; 
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Table S4. Relationship between baseline SGRQ symptom score and exacerbations in control arm in 
Mannitol study
Exacerbations 　 Time to first exacerbations
SGRQ symptom score
Rate ratio         (95% CI)
p value 　
Hazard ratio        (95% 
CI)
p value
Uncategorized score         
(unadjusted)
1.15 (1.05-1.26) 0.004 1.17 (1.08-1.26) <0.001
Uncategorized score 
(adjusted)*
1.14 (1.03-1.25) 0.01 1.14 (1.05-1.24) 0.002
Categorized score     
(unadjusted)
  Low (<40) 1
  Moderate (40-70) 1.41 (0.71-2.84) 0.33 1.54 (0.80-2.97) 0.20
  High (>70) 1.97 (0.98-3.96) 0.06 2.21 (1.14-4.28) 0.02
Categorized score     
(adjusted)*
  Low (<40) 1 1
  Moderate (40-70) 1.41 (0.69-2.90) 0.34 1.54 (0.79-3.02) 0.21
  High (>70) 1.91 (0.93-3.95) 0.08 　 2.09 (1.06-4.12) 0.03
*Adjust for age, gender, BMI, FEV1 % of predicted, smoking status, Pseudomonas aeruginosa isolation, 
Haemophilus influenzae isolation, Moraxella catarrhalis isolation, radiological score, idiopathic bronchiectasis, 
post-infective bronchiectasis
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